APA (7th ed.) Citation

Thuluva, S., Matur, R. V., Gunneri, S., Mogulla, R. R., Thammireddy, K., Peta, K. K., . . . Siddaiah, P. Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: A phase 3, single-blind, randomized, active-controlled study. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Thuluva, Subhash, et al. Immunogenicity and Safety of a Multi-human Dose Formulation of Biological E’s 14-valent Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX 14®) Administered to 6–8-week-old Healthy Infants: A Phase 3, Single-blind, Randomized, Active-controlled Study. Frontiers Media S.A.

MLA (9th ed.) Citation

Thuluva, Subhash, et al. Immunogenicity and Safety of a Multi-human Dose Formulation of Biological E’s 14-valent Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX 14®) Administered to 6–8-week-old Healthy Infants: A Phase 3, Single-blind, Randomized, Active-controlled Study. Frontiers Media S.A.